UBE2M

NEDD8-conjugating enzyme Ubc12

25,815 patent compounds predicted against UBE2M, 10,898 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL1449475)	0.65	19/20
SCHEMBL548246	0.55	17/20
SCHEMBL1449195	0.55	17/20
Hydrochloric Acid (SCHEMBL1449018)	0.53	17/20
SCHEMBL341274	0.65	16/20
SCHEMBL549026	0.64	16/20
SCHEMBL548245	0.58	16/20
Hydrochloric Acid (SCHEMBL1449486)	0.57	16/20
Hydrochloric Acid (SCHEMBL1450004)	0.55	15/20
Hydrochloric Acid (SCHEMBL1449229)	0.55	15/20
SCHEMBL342885	0.53	15/20
SCHEMBL549106	0.60	14/20
SCHEMBL548234	0.57	14/20
Hydrochloric Acid (SCHEMBL1450154)	0.55	14/20
SCHEMBL340688	0.52	14/20
SCHEMBL653373	0.36	14/20
SCHEMBL653374	0.36	14/20
Hydrochloric Acid (SCHEMBL1449606)	0.54	13/20
Hydrochloric Acid (SCHEMBL1448790)	0.51	13/20
Hydrochloric Acid (SCHEMBL1448769)	0.49	13/20

Germline variants in UBE2M on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full UBE2M gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to UBE2M by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome	PHASE2/PHASE3	NOT_YET_RECRUITING
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)	PHASE3	ACTIVE_NOT_RECRUITING
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals	PHASE2	UNKNOWN
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation	PHASE1/PHASE2	COMPLETED
Personalized Antisense Oligonucleotide for A Single Participant With UBTF Gene Mutation	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients	PHASE2	COMPLETED
Olaparib in Patients With HRD Malignant Mesothelioma	PHASE2	RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity	PHASE2	RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)	PHASE1	COMPLETED
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers	PHASE1	COMPLETED
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis	PHASE1	RECRUITING
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	PHASE1	COMPLETED
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine	PHASE1	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome	nan	RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2	nan	NOT_YET_RECRUITING
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2	nan	UNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a UBE2M binder may also engage these)

Protein	Name	Similarity
P61082	—	1.000	P61082 →
A3KN22	—	1.000	A3KN22 →
Q6P8D9	—	1.000	Q6P8D9 →
Q6DCZ9	—	1.000	Q6DCZ9 →
Q9VSF3	—	0.999	Q9VSF3 →
Q6C9W0	—	0.993	Q6C9W0 →
O74549	—	0.993	O74549 →
Q9SDY5	—	0.992	Q9SDY5 →
Q9ZU75	—	0.992	Q9ZU75 →
Q6NY82	—	0.991	Q6NY82 →
Q1RMW1	—	0.989	Q1RMW1 →
Q9CY34	—	0.989	Q9CY34 →
Q5ZKX6	—	0.988	Q5ZKX6 →
Q55EY8	—	0.987	Q55EY8 →
Q6CSW8	—	0.987	Q6CSW8 →
Q5M8Y2	—	0.986	Q5M8Y2 →
Q7ZY08	—	0.986	Q7ZY08 →
Q6FVQ8	—	0.986	Q6FVQ8 →
Q9XWF6	—	0.985	Q9XWF6 →
Q712K3	—	0.985	Q712K3 →
Q6ZWZ2	—	0.985	Q6ZWZ2 →
Q3UWQ3	—	0.984	Q3UWQ3 →
Q5U203	—	0.984	Q5U203 →
P62253	—	0.983	P62253 →
Q95017	—	0.983	Q95017 →
P52482	—	0.983	P52482 →
Q29503	—	0.983	Q29503 →
Q9CQ37	—	0.982	Q9CQ37 →
Q969M7	—	0.982	Q969M7 →
Q28CQ4	—	0.982	Q28CQ4 →